332 related articles for article (PubMed ID: 11363901)
21. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
[TBL] [Abstract][Full Text] [Related]
22. Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia.
Sabin CA; Lepri AC; Devereux H; Phillips AN; Loveday C; Lee CA
J Infect Dis; 2001 Aug; 184(4):511-4. PubMed ID: 11471111
[TBL] [Abstract][Full Text] [Related]
23. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.
Churdboonchart V; Moss RB; Sirawaraporn W; Smutharaks B; Sutthent R; Jensen FC; Vacharak P; Grimes J; Theofan G; Carlo DJ
AIDS; 1998 Aug; 12(12):1521-7. PubMed ID: 9727574
[TBL] [Abstract][Full Text] [Related]
24. Vaccines repress HIV in children.
AIDS Patient Care STDS; 1996 Dec; 10(6):381. PubMed ID: 11361573
[No Abstract] [Full Text] [Related]
25. In brief: immune based therapies.
Proj Inf Perspect; 1999 Sep; (28):24. PubMed ID: 11367364
[TBL] [Abstract][Full Text] [Related]
26. HIV immunotherapeutic vaccines.
Peters BS
Antivir Chem Chemother; 2000 Sep; 11(5):311-20. PubMed ID: 11142629
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
[TBL] [Abstract][Full Text] [Related]
28. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.
Moss RB; Wallace MR; Steigbigel RT; Morrison SA; Giermakowska WK; Nardo CJ; Diveley JP; Carlo DJ
Clin Exp Immunol; 2002 May; 128(2):359-64. PubMed ID: 11985528
[TBL] [Abstract][Full Text] [Related]
29. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.
Muñoz-Fernández MA; Obregón E; Navarro J; Börner C; Gurbindo MD; Sampelayo TH; Fernández-Cruz E
Pediatr Res; 1996 Oct; 40(4):597-602. PubMed ID: 8888289
[TBL] [Abstract][Full Text] [Related]
30. A primer on HIV type 1-specific immune function and REMUNE.
Moss RB; Giermakowska WK; Savary JR; Theofan G; Daigle AE; Richieri SP; Jensen FC; Carlo DJ
AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S167-75. PubMed ID: 9672235
[TBL] [Abstract][Full Text] [Related]
31. Rebuilding the immune system: promising new therapy uses the HIV virus itself to awaken the damaged immune system. Interview by Brian Coppedge and Dan Dawson.
Moss R
STEP Perspect; 1998; 98(2):13-6. PubMed ID: 11365540
[TBL] [Abstract][Full Text] [Related]
32. Remune bites the dust...again.
Vázquez E
Posit Aware; 2001; 12(5):21. PubMed ID: 11688479
[No Abstract] [Full Text] [Related]
33. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
Schüpbach J
AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.
Limsuwan A; Churdboonchart V; Moss RB; Sirawaraporn W; Sutthent R; Smutharaks B; Glidden D; Trauger R; Theofan G; Carlo D
Vaccine; 1998; 16(2-3):142-9. PubMed ID: 9607022
[TBL] [Abstract][Full Text] [Related]
35. AIDS vaccine trial disappointing.
Science; 1996 Apr; 272(5260):341. PubMed ID: 8602519
[No Abstract] [Full Text] [Related]
36. New technologies for quantifying HIV: amplification assays directly measure the virus at all stages of infection.
J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):14-5. PubMed ID: 11362970
[TBL] [Abstract][Full Text] [Related]
37. AIDS vaccines. Immune Response Corp.--take two.
Cohen J
Science; 1994 Jun; 264(5164):1402. PubMed ID: 7910980
[No Abstract] [Full Text] [Related]
38. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
40. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
